ArticleWorld journal of gastroenterology2021
Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion,
Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Anthocyanin-mediated epigenetic modifications: a new perspective in health promoting and disease prevention.Journal of advanced research · 2026Review
- Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.Experimental hematology & oncology · 2026Review
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Article
- Effects of the Polar Fraction ofInternational journal of molecular sciences · 2025Article
- Anthocyanins: From Natural Colorants to Potent Anticancer Agents.Food science & nutrition · 2025Review
- Anti-Inflammatory and Anticancer Effects of Anthocyanins in In Vitro and In Vivo Studies.Antioxidants (Basel, Switzerland) · 2024Review
- Integrating molecular, biochemical, and immunohistochemical features as predictors of hepatocellular carcinoma drug response using machine-learning algorithms.Frontiers in molecular biosciences · 2024Article
- Biologic activity and treatment resistance to gastrointestinal cancer: the role of circular RNA in autophagy regulation.Frontiers in oncology · 2024Review
- The Role of Cyanidin-3-Nutrients · 2023Article
- Maize Flavonoid Biosynthesis, Regulation, and Human Health Relevance: A Review.Molecules (Basel, Switzerland) · 2022Review
- Molecular and genetic markers in hepatocellular carcinoma:World journal of gastrointestinal pathophysiology · 2022Article
- Cancer chemopreventive potential of cooked glutinous purple rice on the early stages of hepatocarcinogenesis in rats.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyanidin-3-O-glucoside (cyan) exhibits antioxidant and anticancer properties. The cell cycle proteins and antimitotic drugs might be promising therapeutic targets in hepatocellular carcinoma.
aimTo investigate the effect of cyan administration on cell cycle in hepatic precancerous lesion (PCL) induced by diethylnitrosamine/2-acetylaminofluorene (DEN/2-AAF) in Wistar rats.
methods
resultsCyan administration mitigated the effect of DEN/2-AFF induced PCL, decreased AFP levels, and improved liver function. Remarkably, treatment with cyan dose dependently decreased the long non-coding RNA MALAT1 and tubulin gamma 1 mRNA expressions and increased the levels of miR-125b, all of which are involved in cell cycle and mitotic spindle assembly. Of note, cyan decreased GSTP foci percent area and PCNA positively stained nuclei.
conclusionOur results indicated that cyan could be used as a potential therapeutic agent to inhibit liver carcinogenesis in rat model
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.